Digital A look back at 2023: A Benchling biotech breakfast As we enter the New Year, and set forth into the myriad possibilities and plans of 2024, it pays to pause and reflect.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
